NF-κB in cancer: A matter of life and death

Cancer Discovery

Volumn 1, Issue 6, 2011, Pages 469-471

  Aggarwal, Bharat B ^a   Sung, Bokyung ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYLAMINO) 1, 8 DIMETHYLIMIDAZO [1, 2 A] QUINOXALINE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ATM PROTEIN; BORTEZOMIB; CETUXIMAB; CYTOKINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL INVASION; CELL METASTASIS; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMOSENSITIVITY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TOXICITY;

ANIMALS; HUMANS; MELANOMA; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84866641762     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0260     Document Type: Article

References (14)

1. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
2. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: 'one size does not fit all.' Oncogene 2011;30:1615-30.
3. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
4. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
5. Enzler T, Sano Y, Choo M, Cottam H, Karin M, Tsao H, et al. Cellselective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discovery 2011;1:496-507.
6. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-wB activation in human melanoma cells. Cancer Res 2001;61:4901-9.
7. Schon M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vohringer V, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 2008;100:862-75.
8. Amschler K, Schon MP, Pletz N, Wallbrecht K, Erpenbeck L, Schon M. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. J Invest Dermatol 2010;130:1073-86.
9. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, et al. The nuclear transcription factor kappaB/ bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 2005;11:8398-402.
10. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-54.
11. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25:3930-5.
12. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009;30:85-94.
13. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NFkappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;1799:775-87.
14. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 2010;76:1044-63.